<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121251</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00108</org_study_id>
    <secondary_id>NCI-2009-00108</secondary_id>
    <secondary_id>CDR0000434851</secondary_id>
    <secondary_id>0501007709</secondary_id>
    <secondary_id>6981</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT00121251</nct_id>
  </id_info>
  <brief_title>Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of sorafenib, gemcitabine,&#xD;
      and capecitabine and to see how well they work in treating patients with unresectable and/or&#xD;
      metastatic kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      sorafenib together with gemcitabine and capecitabine may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of sorafenib&#xD;
      administered in combination with gemictabine and capecitabine in patients with advanced renal&#xD;
      cell carcinoma.&#xD;
&#xD;
      II. Determine the objective response rate for sorafenib in combination with gemictabine and&#xD;
      capecitabine in patients with advanced renal cell carcinoma.&#xD;
&#xD;
      III. Determine the duration of overall survival and progression free survival in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, non-randomized, phase I dose-escalation study followed by a&#xD;
      phase II study.&#xD;
&#xD;
      PHASE I: Patients receive sorafenib* orally (PO) twice daily (BID) on days 1-21, gemcitabine&#xD;
      intravenously (IV) over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14.&#xD;
      Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable&#xD;
      toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of sorafenib, gemcitabine, and capecitabine&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6&#xD;
      patients are treated at the MTD.&#xD;
&#xD;
      Note: *Patients who complete at least 3 courses of treatment with objective response or&#xD;
      stable disease but are deemed poor candidates for continued chemotherapy may continue&#xD;
      treatment with sorafenib&#xD;
&#xD;
      PHASE II: Patients receive sorafenib 200mg orally twice a day on days 1-21, gemcitabine 750&#xD;
      mg/m2 intravenously on days 1 &amp; 8, and capecitabine 415 mg/m2 orally twice a day on days 1-14&#xD;
      of each 21 day cycle, as in phase I at the MTD determined in phase I.&#xD;
&#xD;
      After completion of study treatment patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2005</start_date>
  <completion_date type="Actual">March 14, 2017</completion_date>
  <primary_completion_date type="Actual">March 14, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Number of Months of Progression Free Survival (PFS)</measure>
    <time_frame>From the time of the patient's initial best response (PR or CR) until documented progression, assessed up to 9 years</time_frame>
    <description>PFS will be measured from the time of the patient's initial best response (PR or CR) until documented progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Survived (Overall Survival)</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Overall survival (OS) is defined as the time from start of treatment to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Recurrent Renal Cell Carcinoma</condition>
  <condition>Stage III Renal Cell Cancer AJCC v7</condition>
  <condition>Stage IV Renal Cell Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Sorafenib + Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Sorafenib + Gemcitabine + Capecitabine</arm_group_label>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Sorafenib + Gemcitabine + Capecitabine</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Sorafenib + Gemcitabine + Capecitabine</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed renal cell carcinoma that&#xD;
             is unresectable and/or metastatic; patients with collecting duct carcinoma,&#xD;
             oncocytomas, or transitional cell carcinoma are not eligible; patients with&#xD;
             sarcomatoid renal cell carcinoma are eligible, but those with pure sarcomas are not;&#xD;
             histologic documentation of metastatic disease is not required; clinical confirmation,&#xD;
             but not pathologic staging, of metastatic disease is required&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=&#xD;
             20 mm with conventional techniques or as &gt;= 10 mm with spiral computed tomography (CT)&#xD;
             scan&#xD;
&#xD;
          -  Patients may have received one prior immunotherapy based regimen (i.e. interleukin-2&#xD;
             or interferon alpha) ending &gt;= 4 weeks prior to enrollment&#xD;
&#xD;
          -  Patients may have received up to 2 prior regimens containing mitogen-activated protein&#xD;
             kinases (MAPK), vascular endothelial growth factor (VEGF) pathway inhibitors (e.g.&#xD;
             sunitinib or bevacizumab) and/or mammalian target of rapamycin (mTOR) inhibitor (e.g.&#xD;
             temsirolimus) ending &gt;= 4 weeks prior to enrollment&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) =&lt; 2 OR Karnofsky &gt;= 60%&#xD;
&#xD;
          -  Leukocytes &gt;= 3000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/uL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (IULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x IULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x IULN OR creatinine clearance &gt;= 60 mL/min/1.73m^2 for patients&#xD;
             with creatinine levels above institutional normal&#xD;
&#xD;
          -  The effects of sorafenib on the developing human fetus at the recommended therapeutic&#xD;
             dose are unknown; for this reason and because raf kinase inhibitor agents as well as&#xD;
             other therapeutic agents used in this trial are known to be teratogenic, women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for the duration&#xD;
             of study participation; should a woman become pregnant or suspect she is pregnant&#xD;
             while participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not have received prior chemotherapy; if patients have had prior&#xD;
             definitive or other surgery, prior radiation therapy, they must have fully recovered&#xD;
             from the effects of therapy with at least 4 weeks recovery time; for patients who have&#xD;
             had a surgical biopsy only, they must have simply recovered&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with known active brain metastases should be excluded from this clinical&#xD;
             trial because of their poor prognosis and because they often develop progressive&#xD;
             neurologic dysfunction that would confound the evaluation of neurologic and other&#xD;
             adverse events; previously treated brain metastases are allowed if they show no&#xD;
             evidence of progression on CT or magnetic resonance imaging (MRI) at least 8 weeks&#xD;
             after completion of surgery and/or radiotherapy&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to sorafenib, gemcitabine and capecitabine&#xD;
&#xD;
          -  No concurrent megestrol is permitted; no megestrol therapy within 4 weeks prior to&#xD;
             protocol treatment is allowed; no concurrent cytochrome P450 enzyme-inducing&#xD;
             antiepileptic drugs (phenytoin, phenobarbitol or carbamazepine), rifampin, or St.&#xD;
             John's wort&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled&#xD;
             hypertension, ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, pulmonary disease including asthma,&#xD;
             chronic bronchitis, emphysema with requirements for chronic oxygen use or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because sorafenib is a kinase inhibitor&#xD;
             agent with the potential for teratogenic or abortifacient effects; because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with sorafenib, breastfeeding should be discontinued if the&#xD;
             mother is treated with sorafenib; the potential risks may apply to other agents used&#xD;
             in this study&#xD;
&#xD;
          -  Because patients with immune deficiency are at increased risk of lethal infections&#xD;
             when treated with marrow-suppressive therapy, human immunodeficiency virus&#xD;
             (HIV)-positive patients receiving combination anti-retroviral therapy are excluded&#xD;
             from the study because of possible pharmacokinetic interactions with sorafenib,&#xD;
             gemcitabine, or capecitabine administered during the study; appropriate studies will&#xD;
             be undertaken in patients receiving combination ant-retroviral therapy when indicated&#xD;
&#xD;
          -  Any swallowing dysfunction leading to difficulty taking the investigational therapy or&#xD;
             capecitabine&#xD;
&#xD;
          -  Prior treatment with sorafenib&#xD;
&#xD;
          -  Patients with any history or evidence of a bleeding diathesis&#xD;
&#xD;
          -  Patients on therapeutic anticoagulation with coumarins (e.g. warfarin); prophylactic&#xD;
             coumarin-based anticoagulation (i.e. low dose warfarin) for venous or arterial access&#xD;
             devices is allowed provided that the requirements for prothrombin time (PT),&#xD;
             international normalization ratio (INR) and/or partial thromboplastin time (PTT) are&#xD;
             met; prophylactic or therapeutic low molecular weight heparin is allowed; patients&#xD;
             with known brain metastases are excluded (even if treated and stable) if they are also&#xD;
             on therapeutic doses of anticoagulation&#xD;
&#xD;
          -  Patients with known dihydropyrimidine dehydrogenase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Tagawa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center - Moses Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <results_first_submitted>April 30, 2019</results_first_submitted>
  <results_first_submitted_qc>March 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 23, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT00121251/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study opened to enrollment in June 2005 and closed to enrollment September 2011. Patients were recruited from the inpatient and outpatient clinics at Weill Cornell Medical Center, Columbia University Medical Center, North Shore Hospital, New York University Hospital, Montefiore Medical Center, Mount Sinai Medical Center and others</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib + Gemcitabine + Capecitabine</title>
          <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.&#xD;
Capecitabine: Given PO&#xD;
Gemcitabine Hydrochloride: Given IV&#xD;
Sorafenib Tosylate: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib + Gemcitabine + Capecitabine</title>
          <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.&#xD;
Capecitabine: Given PO&#xD;
Gemcitabine Hydrochloride: Given IV&#xD;
Sorafenib Tosylate: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="41" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0 Normal Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Symptoms, but ambulatory. Restricted in strenuous activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Capable of all self-care but unable to carry out any work activities. In bed &lt;50% of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Papillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sarcomatoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chromophobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of Metastasis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lung/Pleura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Viscera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 or more sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Nephrectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytokines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sunitinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MSK Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Favorable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR</description>
        <time_frame>Up to 9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Gemcitabine + Capecitabine</title>
            <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.&#xD;
Capecitabine: Given PO&#xD;
Gemcitabine Hydrochloride: Given IV&#xD;
Sorafenib Tosylate: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Months of Progression Free Survival (PFS)</title>
        <description>PFS will be measured from the time of the patient's initial best response (PR or CR) until documented progression.</description>
        <time_frame>From the time of the patient's initial best response (PR or CR) until documented progression, assessed up to 9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Gemcitabine + Capecitabine</title>
            <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.&#xD;
Capecitabine: Given PO&#xD;
Gemcitabine Hydrochloride: Given IV&#xD;
Sorafenib Tosylate: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Months of Progression Free Survival (PFS)</title>
          <description>PFS will be measured from the time of the patient's initial best response (PR or CR) until documented progression.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Survived (Overall Survival)</title>
        <description>Overall survival (OS) is defined as the time from start of treatment to death from any cause.</description>
        <time_frame>Up to 9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Gemcitabine + Capecitabine</title>
            <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.&#xD;
Capecitabine: Given PO&#xD;
Gemcitabine Hydrochloride: Given IV&#xD;
Sorafenib Tosylate: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived (Overall Survival)</title>
          <description>Overall survival (OS) is defined as the time from start of treatment to death from any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 9 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib + Gemcitabine + Capecitabine</title>
          <description>Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.&#xD;
Capecitabine: Given PO&#xD;
Gemcitabine Hydrochloride: Given IV&#xD;
Sorafenib Tosylate: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-Plantar Erythrodysesthesia Syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cooperative Group Program Manager</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>646-962-9377</phone>
      <email>has7003@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

